Abstract

Backround. Omega-3 fatty acids, such as those present in fish oil, have been reported to prolong life in survivors of myocardial infarction. Recent prospective evidence shows that 1 mmol/l increase in plasma triglyceride concentration increases cardiovascular risk in men 30% and in women up to 76%.

Experimental and pharmacological studies have shown that omega-3 fatty acids reduce serum triglyceride levels in a dose-dependent manner. The primary mechanisms involve suppression of hepatic very low density lipoprotein and triglyceride production.

The aim of the study was to examine the triglyceride lowering effect of Bio-Marin Natural (Pharma Nord), a concentrate of omega-3, over eight weeks in patients with combined dyslipidaemia without coronary artery disease who are not receiving statin therapy.

Material and methods. Fifteen patients with fasting hypertriglyceridaemia ≥ 2.0 mmol/l were given 1. 2 g omega-3 for 8 weeks. The fasting lipid profile was analysed before and after the 8-week study period. Average age was 54 years and mean BMI was 29 kg/m^2.

Results. As a result, 4 capsules of Bio-Marin Natural per day lowered serum triglycerides significantly, by 27,.4 % (p <0.001) and did not have any effect on the other lipid parameters. Interestingly, the effect of the same dose of omega-3 on lowering triglycerides differed largely and up to 60%.

Conclusion. Thus, 1.2 g of omega-3 per day significantly lowered serum triglycerides up to 60% over 8 weeks in patients with combined hyperlipidaemia.